Publications by authors named "S Bezares"
Cross-sectional and longitudinal associations of adherence to WCRF/AICR cancer prevention recommendations with health-related quality of life in breast cancer survivors. Health-EpiGEICAM study.
J Nutr Health Aging
August 2024
Article Synopsis
- - The study investigates how following cancer prevention guidelines from the WCRF/AICR affects the health-related quality of life (HRQL) in breast cancer survivors over a long period, specifically comparing their status at diagnosis and 7-12 years later.
- - Researchers analyzed data from 406 breast cancer survivors, collecting information on lifestyle, diet, physical activity, and HRQL using a scoring system based on WCRF/AICR recommendations.
- - Results indicate that higher adherence to these cancer prevention guidelines is linked to slight improvements in the physical aspect of HRQL over time, while no significant change was found in the mental HRQL domain.
Background: Retrospective data suggest an association between bevacizumab efficacy and the incidence of arterial hypertension (AHT). Additionally, epigenetic mechanisms have been related to AHT.
Methods: This prospective observational study conducted by GEICAM Spanish Breast Cancer Research Group included metastatic breast (MBC) or colorectal (mCRC) cancer patients treated with bevacizumab-containing chemotherapy as first-line treatment.
Background: In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression-free survival (PFS) compared with placebo/fulvestrant in postmenopausal women with HR+/HER2- advanced breast cancer (ABC).
Objective: We assessed health-related quality of life (QoL) using patient-reported outcomes (PROs).
Design And Methods: In this phase II double-blinded study, PROs were assessed at baseline after every three cycles and at the end of the treatment using the European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-BR23.
Background: We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and the pyrimidine antimetabolite gemcitabine in HER2- advanced breast cancer (ABC) patients previously treated in the advanced setting, in order to explore a potential synergism that could eventually obtain long term benefit in these patients.
Methods: HER2-negative ABC patients received 21-day cycles of pembrolizumab 200 mg (day 1) and gemcitabine (days 1 and 8). A run-in-phase (6 + 6 design) was planned with two dose levels (DL) of gemcitabine (1,250 mg/m [DL0]; 1,000 mg/m [DL1]) to determine the recommended phase II dose (RP2D).
Breast cancer (BC) survivors are advised to follow the WCRF/AICR cancer prevention recommendations, given their high risk of developing a second tumour. We aimed to explore compliance with these recommendations in BC survivors and to identify potentially associated clinical and sociodemographic factors. A total of 420 BC survivors, aged 31-80, was recruited from 16 Spanish hospitals.
View Article and Find Full Text PDF